148 related articles for article (PubMed ID: 3178156)
1. A new tumor marker MCA in breast cancer diagnosis.
Eskelinen M; Tikanoja S; Collan Y
Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
Eskelinen M; Tikanoja S; Brown J
Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours.
Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y
Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
[TBL] [Abstract][Full Text] [Related]
6. MCA performance in preoperative breast cancer patients.
Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
[TBL] [Abstract][Full Text] [Related]
8. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
Cappellari A; Bagarella M; Corradi G
Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical staining of human breast cancer with a new tumour marker MCA: relation to axillary lymph node involvement, metastasis, and survival.
Eskelinen M; Lipponen P; Collan Y
Anticancer Res; 1990; 10(3):591-6. PubMed ID: 1695077
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
[TBL] [Abstract][Full Text] [Related]
13. The role of CA 15-3 and MCA monoclonal antibody assays in the detection of primary and recurrent breast cancer.
Pirolo F; Pacini P; Borsotti M; la Morgia R; Mungai R; Cappellini M; Cardona G; Cataliotti L; Marzano S; Neri B
Anticancer Res; 1991; 11(2):729-31. PubMed ID: 2064326
[TBL] [Abstract][Full Text] [Related]
14. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
15. Efficient test for cancer antigens: decreased levels of cancer antigen in serum after excision of breast tumor.
Eskelinen M; Tikanoja S; Collan Y
Anticancer Res; 1989; 9(2):437-9. PubMed ID: 2751269
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of mucinous-like cancer antigen (MCA) in women with breast disease: preliminary results.
Valenti G; Zanardi S; Valtolina M; Bombardieri E; Boccardo F
Cancer Detect Prev; 1991; 15(4):285-9. PubMed ID: 1794135
[TBL] [Abstract][Full Text] [Related]
17. [Tumor markers MCA and CA-125 in the diagnosis and monitoring of breast cancer].
Shakhtarin VV; Izotova IA; Parshkov EM; Chekin SIu; Simakova GM
Vopr Onkol; 1992; 38(4):433-9. PubMed ID: 1300737
[TBL] [Abstract][Full Text] [Related]
18. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
19. The serum tumor marker M3/M21 in the follow-up of breast cancer patients.
Tempfer C; Hanzal E; Zeillinger R; Koelbl H; Dadak C; Kainz C
Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765
[TBL] [Abstract][Full Text] [Related]
20. [MCA and CA 15-3 in the follow-up of patients with breast cancer].
Hammer J; Track C; Hohenwallner W; Seewald DH; Zoidl JP; Wimmer E
Strahlenther Onkol; 1992 Feb; 168(2):102-6. PubMed ID: 1542844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]